United Therapeutics reported $7.03B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Amarin USD 634.08M 9.72M Sep/2026
Ardelyx USD 587.52M 11.63M Sep/2026
Baxter International USD 19.41B 377M Sep/2026
Bayer EUR 113.47B 6.18B Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Insmed USD 2.23B 123.49M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Moderna USD 13.47B 2.51B Sep/2026
Omeros USD 200.57M 34.59M Jun/2025
Pfizer USD 204.54B 3.41B Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Teva Pharmaceutical Industries USD 40.04B 185M Sep/2026
United Therapeutics USD 7.03B 186M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026